ArticleHealth science reports2026
Ocular Complications in Patients With Transfusion-Dependent Beta-Thalassemia Receiving Deferasirox: A Cross-Sectional Study.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Transfusion-dependent beta-thalassemia is a chronic hematologic disorder necessitating lifelong blood transfusions and iron chelation therapy, which can lead to systemic and ocular complications. This study aimed to assess the frequency and characteristics of ocular complications in beta-thalassemia patients treated with deferasirox. Methods: In this cross-sectional study, 75 patients with transfusion-dependent beta-thalassemia receiving deferasirox for at least 1 year were evaluated. Demographic and clinical characteristics, including hemoglobin (Hb) and ferritin levels over 6 months, were collected. Comprehensive ophthalmological assessments included best corrected visual acuity (BCVA), refraction, slit-lamp, fundus examination, optical coherence tomography (OCT), and fundus autofluorescence (FAF). Data were analyzed using SPSS version 26, and the significance level was set at 0.05. Results: The mean age of the 75 patients was 27.8 ± 8.3 years, and 69.3% were female. The mean duration of deferasirox treatment was 53.6 ± 33.3 months at a daily dose of 24.1 ± 7.99 mg/kg. Mean Hb and ferritin levels were 8.99 ± 2.12 g/dL and 1419.8 ± 1218.6 ng/mL, respectively. Cataracts were identified in 7 of 75 patients (9.3%), with bilateral involvement in all affected patients. Ophthalmologic measurements were analyzed separately for each eye. BCVA showed a positive correlation with Hb in the right eye ( Conclusion: Ocular abnormalities were observed in patients with transfusion-dependent beta-thalassemia receiving deferasirox therapy. Longitudinal controlled studies are required to clarify the contribution of deferasirox to these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.